- Lotus today successfully completed its 2022 AGM to approve all the proposals by the Board of Directors, including a cash distribution of NT$1.93 per share to shareholders.
- Three new directors appointed by AEMH were also elected during the meeting to form a stronger Board of Directors with comprehensive industry experience and geographical reach to guide the next phase of development for Lotus to become a global leader.
Taipei, Taiwan, June 30 2022 -- Lotus Pharmaceuticals Co., Ltd. (“Lotus” or “the Company”, TWSE ticker: 1795), a multinational pharmaceutical company, today held its 2022 Annual General Shareholders’ Meeting in Taipei. In addition to adopting all resolutions submitted to the vote, which included a cash distribution of NT$1.93 per share, the shareholders also elected three additional directors nominated by the Board of Directors of the Company.
The three newly-elected directors are recommended and appointed as the representatives of Lotus’s major shareholder, Alvogen Emerging Markets Holding Limited (“AEMH”), further to the joint force of Aztiq and Innobic acquiring the 100% stake in AEMH earlier this year. All the three directors have comprehensive experience and in-depth expertise in the fields they’ve involved – Mr. Yves Hermes has been working in Asia since 2000, heading Zuellig Pharma Taiwan, Thailand, and serving as Area Director for South East Asia at Zuellig Pharma International Services before he founded his own healthcare consultancy company in 2021. Ms. Oranee Tangphao-Daniels has more than 30 years in pharma industry and now is the Chief Medical Officer at Antiva Biosciences, a novel topical therapies development company focusing on pre-cancerous lesions caused by HPV. Ms. Phannalin Mahawongtikul is the Chief Financial Officer of PTT Public Company Ltd. and currently is also a member of the Risk Management Committee at Thai Oil Public Company Ltd. With the participation of the three new directors, Lotus now has eleven directors, among which three are independent directors, with a balanced diversity of professions, experiences, as well as gender.
Róbert Wessman, Chairman of Lotus, commented: “we are honored to have more industry veterans across different sectors to lead the Company toward the next phase of development. By leveraging the strong expertise from all the directors, Lotus now is in a great position to become the most potential contender in the global pharma industry.”
The new Board of Directors will further assist Lotus in paving the way for the regional expansion in ASEAN countries and continuously supporting Lotus’s existing strategy to fuel the growth by bringing new opportunities, experience and resources.